Your shopping cart is currently empty

SNAP 94847 (SNAP-94847) is a selective and competitive MCH1 receptor (MCH1-R) antagonist (Ki: 2.2 nM). It has anxiolytic and antidepressant activity and reduces food intake in mice.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $45 | In Stock | In Stock | |
| 5 mg | $98 | In Stock | In Stock | |
| 10 mg | $166 | In Stock | In Stock | |
| 25 mg | $332 | In Stock | In Stock | |
| 50 mg | $565 | In Stock | In Stock | |
| 100 mg | $955 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $112 | In Stock | In Stock |
| Description | SNAP 94847 (SNAP-94847) is a selective and competitive MCH1 receptor (MCH1-R) antagonist (Ki: 2.2 nM). It has anxiolytic and antidepressant activity and reduces food intake in mice. |
| Targets&IC50 | MCH1R:2.2 nM (Ki, cell free) |
| In vitro | SNAP-94847 showed a favorable combination of MCH1 receptor affinity (Ki: 2.2 nM) and human R1A receptor (>80-fold) and D2 (>500-fold) selectivity [1]. |
| In vivo | SNAP-94847 (10 mg/kg, p.o.) had no effect on basal water consumption measured over 2 h: vehicle-treated (2.0 mL); 16g-treated (2.3 mL). MCH-evoked water intake was inhibited significantly by SNAP-94847 at doses of 1.0, 2.5, and 10 mg/kg [1]. BALB/c mice treated for 21 days with fluoxetine or SNAP 94847 (20 mg/kg/day) showed marked increases in quinpirole-induced locomotor activity, with the onset of hyper-locomotion appearing earlier in the time course after SNAP 94847 compared to fluoxetine. Administration of either compound for 7 days was also sufficient to augment the quinpirole response in BALB/c mice [2]. The intra-locus coeruleus and intracerebroventricular injections of melanin-concentrating hormone and chronic injections of corticosterone increased immobility time in the forced swim test and decreased sucrose preference in the sucrose preference test. All these depressive-like behaviors were reversed by an intra-locus coeruleus microinjection of SNAP-94847 [3]. |
| Animal Research | Chronically treated Sprague–Dawley rats were administered fluoxetine (18 mg/kg/day) or SNAP 94847 (20 mg/kg/day) via oral gavage in 20% beta-cyclodextrin for 2 weeks (1 injection, 6 h into light cycle). For acute treatment, drugs were given orally in 20% betacyclodextrin 1 h before testing. On each test day, locomotor activity was recorded during a 60 min habituation to the novel locomotor cage, after which the rats were administered quinpirole (0.3 mg/kg, i.p.) and returned immediately to the cage, where locomotor activity was measured for an additional 180 min. In each case-control animals were administered the corresponding vehicle, without drug [2]. |
| Synonyms | SNAP-94847 |
| Molecular Weight | 478.57 |
| Formula | C29H32F2N2O2 |
| Cas No. | 487051-12-7 |
| Smiles | CC=1C(=CC(NC(C(C)C)=O)=CC1)C2CCN(CC3=CC=C(OC4=CC(F)=C(F)C=C4)C=C3)CC2 |
| Relative Density. | no data available |
| Storage | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 20 mg/mL (41.79 mM), Sonication is recommended. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.